Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06512207
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-06
Brief Title:
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Clinical Investigation on the Efficacy of Leuprorelin Acetate Androgen Deprivation Therapy Combined With Sintilimab Anti-PD-1 in Advanced Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Androgen Deprivation Therapy ADT triggers thymic revitalization and increases thymic output enhancing baseline anti-tumor immunity and responses to immunotherapies Anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors This study is to investigate the combination of Leuprorelin ADT and Sintilimab anti-PD-1 therapy in patients with advanced lung cancer
Detailed Description:
Immune checkpoint blockades ICBs are widely used in the clinical treatment of lung cancer Studies have shown that the quantity and function of tumor-infiltrating lymphocytes TILs are associated with the effectiveness of PD-1 inhibitors in treating advanced NSCLC The thymus is crucial for the differentiation development and maturation of T cells With age thymic atrophy leads to immunosenescence significantly affecting baseline anti-tumor immunity and responses to immunotherapies Preliminary findings have indicated that androgen deprivation therapy ADT not only directly induces apoptosis in prostate cancer cells but also may exert anti-tumor effects by promoting thymic regeneration Furthermore anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors Therefore this study aims to investigate the combination of Leuprorelin ADT and Sintilimab anti-PD-1 therapy in patients with advanced lung cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None